U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of ...
PharmiWeb18h
Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia gravis in the Phase 2/3 study
For immediate release Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia gravis in the Phase 2/3 study First FcRn blocker to demonstrate sustained ...
Oncology Nurse Advisor6d
High Dose Intensity Maintenance Therapy May Increase Risk of Toxicity, Relapse in Pediatric ALL
Researchers sought to determine whether high antimetabolite dose intensity is related to higher treatment-induced toxicity in pediatric patients with ALL.
Medscape6d
Wide Availability of Naloxone and Education on Its Use Can Save Pediatric Lives
ORLANDO, Fla. — More than half of youth improved after receiving a dose of naloxone by emergency medical services (EMS) after ...
Medscape3d
The Basics of Pediatric Immunizations
In the early 1950s there were four vaccines routinely used in the United States: diphtheria, tetanus, pertussis, and smallpox. Three of these vaccines (diphtheria, tetanus, and pertussis) were ...
Monthly Prescribing Reference15h
FDA Approves Stelara Biosimilar Imuldosa
The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), ...
News Medical4h
Candida Overgrowth in the Gut
19 Another assessed the effectiveness of probiotics in a pediatric intensive care unit and found that children receiving probiotics while on broad-spectrum antibiotics showed a relative drop in ...
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized ...
News Medical on MSN2d
Can the Mediterranean diet protect against childhood overweight and obesity?
Following the Mediterranean diet may modestly lower children's risk of gaining excessive weight, but the impact was not ...
Targeted Oncology3d
Lipsky Discusses Second-Generation BTK Inhibitors in Relapsed/Refractory CLL
During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...
National Academies of Sciences%2c Engineering%2c and Medicine6d
Health and Medicine Division
The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...
sanofi6d
Proud to Fly the Meningitis Flag!
Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. We’re proud to be premium ...